Research

Sleep Apnea Reduced in People Who Took Weight-Loss Drug, Eli Lilly Reports

The New York Times •
In a study, people with sleep apnea who were randomly assigned to take the weight-loss drug Zepbound had an average of about 30 fewer apnea episodes per hour.Credit...Brendan Mcdermid/Reuters
View Content

The pharmaceutical manufacturer Eli Lilly announced on Wednesday that its obesity drug tirzepatide, or Zepbound, provided considerable relief to overweight or obese people who had obstructive sleep apnea, or episodes of stopped breathing during sleep.